Renal cell carcinoma in children and adolescents

References

• Pastore G, Znaor A, Spreafico F et al. Malignant renal tumours incidence and survival in European children (1978–1997): report from the Automated Childhood cancer Information System project. Eur. J. Cancer42, 2103–2114 (2006).
   PubMed Web of Science ®Google Scholar
• Selle B, Furtwängler R, Graf N, Kaatsch P, Bruder E, Leuschner I. Population-based study of renal cell carcinoma in children in Germany, 1980–2005. More frequently localized tumors and underlying disorders compared with adult counterparts. Cancer107, 2906–2914 (2006).
   Web of Science ®Google Scholar
• Silberstein J, Grabowski J, Saltzstein SL, Kane CJ. Renal cell carcinoma in the pediatric population: results from the California Cancer registry. Pediatr. Blood Cancer52, 237–241 (2009).
   PubMed Web of Science ®Google Scholar
• Argani P, Ladanyi M. Recent advances in paediatric renal neoplasia. Adv. Anat. Path.10, 243–260 (2003).
   PubMed Web of Science ®Google Scholar
• Carcao MD, Taylor GP, Greenberg ML et al. Renal-cell carcinoma in children: a different disorder from its adult counterpart? Med. Ped. Oncol.31, 153–158 (1998).
   Google Scholar
• Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer101, 1575–1583 (2004).
   Google Scholar
• Eble JN, Sauter G, Epstein J et al. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumors. IARC, Lyon, France (2004).
   Google Scholar
• Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int. J. Urol.16, 432–443 (2009).
   PubMed Web of Science ®Google Scholar
• Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin. Lab. Med.25, 363–378 (2005).
   PubMedGoogle Scholar
• Argani P, Ldanyi M. The evolving story of renal translocation carcinomas. Am. J. Clin. Pathol.126, 332–334 (2006).
   PubMedGoogle Scholar
• Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology42, 369–373 (2010).
   PubMed Web of Science ®Google Scholar
• Sausville JE, Hernandez DJ, Argani P, Gearhart JP. Pediatric renal cell carcinoma. J. Pediatr. Urol.5, 308–314 (2009).
   Google Scholar
• Argani P, Olgac S, Tickoo SK et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am. J. Surg. Pathol.31, 1149–1160 (2007).
   PubMed Web of Science ®Google Scholar
• Geller JI, Argani P, Adeniran A et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer112, 1607–1616 (2008).
   PubMedGoogle Scholar
• Wu A, Kunju LP, Cheng L, Shah RB. Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation-associated and unusual clear cell subtype. Histopathology53, 533–544 (2008).
   Google Scholar
• Rao Q, Chen JY, Wang JD et al. Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up. Int. J. Surg. Pathol. DOI: 10.1177/1066896909354337 (2009) (Epub ahead of print).
   Google Scholar
• Indolfi P, Terenziani M, Casale F et al. Renal cell carcinoma in children: a clinicopathologic study. J. Clin. Oncol.21, 530–535 (2003).
   Google Scholar
• Estrada CR, Suthar AM, Eaton SH et al. Renal cell carcinoma: Children’s Hospital Boston experience. Urology66, 1296–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Ramphal R, Pappo A, Zielenska M et al. Pediatric renal cell carcinoma. Clinical, pathologic, and molecular abnormalities associated with the members of the MiT transcription factor family. Am. J. Clin. Pathol.126, 349–364 (2006).
   PubMed Web of Science ®Google Scholar
• Baek M, Jung JY, Kim JJ, Park KH, Ryu DS. Characteristics and clinical outcomes of renal cell carcinoma in children: a single center experience. Int. J. Urol.17(8), 737–740 (2010).
   Google Scholar
• Ahmed HU, Arya M, Levitt G, Duffy PG, Sebire NJ, Mushtaq I. Part II: treatment of primary malignant non-Wilms’s renal tumours in children. Lancet Oncol.8, 842–848 (2007).
   PubMedGoogle Scholar
• Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol.18, 581–592 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet373, 1119–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Argani P, Laé M, Ballard ET, Amin M et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J. Clin. Oncol.24, 1530–1534 (2006).
   Google Scholar
• Schafernak KT, Yang XJ, Hsueh W, Leestma JL, Stagl J, Goldman S. Pediatric renal cell carcinoma as second malignancy: reports of two cases and review of the literature. Can. J. Urol.14, 3739–3744 (2007).
   Google Scholar
• Bassal M, Mertens AC, Taylor R et al. Risk of selected subsequent carcinomas in survivor of childhood cancers: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol.24, 476–483 (2006).
   PubMed Web of Science ®Google Scholar
• Indolfi P, Bisogno G, Cecchetto G et al. Local lymph node involvement in pediatric renal cell carcinoma: a report from the Italian TREP project. Ped. Blood Cancer51, 475–478 (2008).
   Google Scholar
• Cook A, Lorenzo AJ, Salle JL et al. Pediatric renal cell carcinoma: single institution 25-year case series and initial experience with partial nephrectomy. J. Urol.175, 1456–1460 (2006).
   Google Scholar
• Gill IS, Aron M, Gervais DA, Jewett MAS. Small renal masses. N. Engl. J. Med.362, 624–634 (2010).
   PubMed Web of Science ®Google Scholar
• Leveridge MJ, Bostrom PJ, Koulouris G, Finelli A, Lawrentschuk N. Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat. Rev. Urol.7, 311–325 (2010).
   Google Scholar
• Miniati D, Gay AN, Parks KV et al. Imaging accuracy and incidence of Wilms’ and non-Wilms’ renal tumors in children. J. Pediatr. Surg.43, 1301–1307 (2008).
   Google Scholar
• Vujanic G, Kelsey A, Mitchell C, Shannon RS, Gornal P. The role of biopsy in the diagnosis of renal tumors in childhood: results of the UKCCSG Wilms tumor study 3. Med. Ped. Oncol.40, 18–22 (2003).
   PubMedGoogle Scholar
• Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol.6, 655–663 (1982).
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Briganti A, Chun FK et al. Multiinstitutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol.25, 1316–1322 (2007).
   PubMed Web of Science ®Google Scholar
• Bruder E, Passera O, Harms D et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am. J. Surg. Pathol.28, 1117–1132 (2004).
   PubMed Web of Science ®Google Scholar
• Sebire NJ, Vujanic GM. Paediatric renal tumours: recent developments, new entities and pathological features. Histopathology54, 516–528 (2009).
   PubMed Web of Science ®Google Scholar
• Camparo P, Vasiliu V, Molinie V et al. Renal translocation carcinomas. Clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am. J. Surg. Pathol.35, 656–670 (2008).
   Google Scholar
• Argani P, Aulmann S, Karanjawala Z et al. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am. J. Surg. Pathol.33, 609–619 (2009).
   PubMed Web of Science ®Google Scholar
• Martignoni G, Pea M, Gobbo S et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Modern Pathol.22, 1016–1022 (2009).
   PubMedGoogle Scholar
• Argani P, Hawkins A, Griffin CA et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am. J. Pathol.158, 2089–2096 (2001).
   PubMed Web of Science ®Google Scholar
• Argani P, Antonescu CR, Illei PB et al. Primary renal neoplasms with the ASPL–TFE3 gene fusion of alveolar soft part sarcoma: a distinct tumor entity previously included among renal cell carcinomas of children and adolescents. Am. J. Pathol.159, 179–192 (2001).
   PubMed Web of Science ®Google Scholar
• Argani P, Lui MY, Couturier J et al. A novel CLTC–TFE3 gene fusion in pediatric renal cell adenocarcinoma with t(X;17)(p11.2;q23). Oncogene22, 5374–5378 (2003).
   PubMed Web of Science ®Google Scholar
• Argani P, Laé M, Hutchinson B et al. Renal carcinoma with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific α-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am. J. Surg. Pathol.29, 230–240 (2005).
   PubMed Web of Science ®Google Scholar
• Arroyo MR, Green DM, Perlman EJ, Beckwith JB, Argani P. The spectrum of metanephric adenofibroma and related lesions. Clinicopathologic study of 25 cases from the National Wilms Tumor Study Group pathology Center. Am. J. Surg. Pathol.25, 433–444 (2001).
   PubMedGoogle Scholar
• Medeiros LJ, Palmedo G, Krigmann HR et al. Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am. J. Surg. Pathol.23, 772–780 (1999).
   PubMedGoogle Scholar
• Nyhan MJ, O’Sullivan GC, McKenna SL. Role of the VHL (von Hippel–Lindau) gene in renal cancer: a multifunctional tumor suppressor. Biochem. Soc. Trans.36, 3472–3478 (2008).
   Google Scholar
• Aronson DC, Medary I, Finlay JL et al. Renal cell carcinoma in childhood and adolescence: a retrospective survey for prognostic factors in 22 cases. J. Pediatr. Surg.31, 183–186 (1996).
   Google Scholar
• Touijer K, Jacqmin D, Kavoussi LR et al. The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur. Urol.57, 214–222 (2010).
   PubMed Web of Science ®Google Scholar
• Ficarra V. Open radical nephrectomy versus open partial nephrectomy: is it still an issue? Eur. Urol.51, 593–595 (2007).
   Google Scholar
• Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma (letter to the Editor). Pediatr. Blood Cancer52, 430 (2009).
   Google Scholar
• Renshaw MD. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer103, 1317–1318 (2005).
   Google Scholar
• Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J.14, 308–314 (2008).
   Google Scholar
• Geller JI, Khoury JD, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma (author reply). Cancer103, 1318 (2005).
   Google Scholar
• Blom JH, van Poppel H, Maréchal JM et al. Radical nephrectomy with and without lymph-node dissection: final results of the European Organization for Research and Treatment of Cancer (EORTC) randomized Phase 3 trial 30881. Eur. Urol.55, 28–34 (2008).
   Google Scholar
• Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cell cancer: a combined analysis. J. Urol.171, 1071–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat. Rev. Urol.7, 327–338 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol.177, 1978–1984 (2007).
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 225 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.13, 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Uchiyama M, Iwafuchi M, Yagi M et al. Treatment of childhood renal cell carcinoma with lymph node metastases: two cases and a review of literature. J. Surg. Oncol.75, 266–269 (2000).
   Google Scholar
• Escudier B. Chemo-immunotherapy in RCC: the end of a story. Lancet375, 613–614 (2010).
   PubMedGoogle Scholar
• Ladanyi M, Lui MY, Antonescu CR et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene20, 48–57 (2001).
   PubMed Web of Science ®Google Scholar
• Goldberg J, Demetri GD, Choy E et al. Preliminary results from a Phase II study of ARQ 197 in patients with microphtalmia transcription factor family (MiT)-associated tumors. J. Clin. Oncol.27, (15 Suppl.) (2009) (Abstract 10502).
   Google Scholar
• Brugarolas J. Renal-cell carcinoma – molecular pathways and therapies. N. Engl. J. Med.356, 185–187 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus inteferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int.103, 572–577 (2009).
   Web of Science ®Google Scholar
• Soulières D. Review of guidelines on the treatment of metastatic renal cell carcinoma. Curr. Oncol.16(Suppl. 1), S67–S70 (2009).
   PubMedGoogle Scholar
• Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon α-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.28, 2144–2150 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27, 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev. Anticancer Ther.10, 635–645 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v137–v139 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther.10(3), 305–317 (2010).
   PubMed Web of Science ®Google Scholar
• Heng DY, Chi KN, Murray N et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer115, 776–783 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer116(18), 4256–4265 (2010).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2- and interferon-α2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br. J. Cancer92, 843–846 (2005).
   PubMed Web of Science ®Google Scholar
• Joshi DD, Banerjee T. Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy. Ped. Blood Cancer50, 903–904 (2008).
   Google Scholar
• Pressey JG, Wright JM, Geller JI et al. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Ped. Blood Cancer54, 1035–1037 (2010).
   Google Scholar
• Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Ped. Blood Cancer46, 527 (2006).
   PubMedGoogle Scholar
• Pwint TP, Macaulay V, Roberts IS, Sullivan M, Prothero A. An adult Xp11.2 translocation renal cell carcinoma showing response to treatment with sunitinib. Urol. Oncol. DOI: 10.10161i.urolonc.2009.10.007 (2009) (Epub ahead of print ).
   PubMedGoogle Scholar
• Malouf GG, Camparo P, Oudard S et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann. Oncol.21(9), 1834–1838 (2010).
   PubMed Web of Science ®Google Scholar
• Fouladi M, Laningham F, Wu J et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J. Clin. Oncol.25, 4806–4812 (2007).
   PubMed Web of Science ®Google Scholar
• Maris JM, Courtright J, Houghton P et al. Initial testing (stage 1) of sunitinib by the Pediatric Preclinical Testing Program. Med. Ped. Oncol.51, 42–48 (2008).
   Google Scholar
• Pastore G, De Salvo GL, Bisogno G et al. Evaluating access to pediatric cancer care centers of children and adolescents with rare tumors in Italy: the TREP Project. Ped. Blood Cancer.53, 152–155 (2009).
   PubMed Web of Science ®Google Scholar
• Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal cell carcinoma reveals inactivation of histone modifying genes. Nature463, 360–363 (2010).
   PubMed Web of Science ®Google Scholar
• Tsuda M, Davis IJ, Argani P et al. TFE3 fusion activates MET signalling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res.67, 919–929 (2007).
   PubMed Web of Science ®Google Scholar
• Ghoneim IA, Fergany AF. Minimally invasive surgery for renal cell carcinoma. Expert Rev. Anticancer Ther.9(7), 989–997 (2009).
   PubMed Web of Science ®Google Scholar
• Heuer R, Gill IS, Guazzoni G et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur. Urol.57, 223–232 (2010).
   PubMed Web of Science ®Google Scholar